Robert W. Baird set a $94.00 price objective on PRA Health Sciences (NASDAQ:PRAH) in a research note released on Friday morning. The brokerage currently has a buy rating on the medical research company’s stock.

PRAH has been the topic of several other research reports. Zacks Investment Research downgraded shares of PRA Health Sciences from a buy rating to a hold rating in a report on Friday, September 15th. SunTrust Banks reissued a buy rating and issued a $101.00 target price on shares of PRA Health Sciences in a report on Friday, October 27th. KeyCorp reissued a buy rating and issued a $93.00 target price (up previously from $86.00) on shares of PRA Health Sciences in a report on Monday, October 30th. Citigroup reissued a buy rating and issued a $93.00 target price (up previously from $90.00) on shares of PRA Health Sciences in a report on Thursday, August 10th. Finally, Mizuho set a $87.00 target price on shares of PRA Health Sciences and gave the stock a buy rating in a report on Friday. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $89.09.

Shares of PRA Health Sciences (PRAH) traded down $0.52 during trading hours on Friday, reaching $81.85. 460,247 shares of the company’s stock traded hands, compared to its average volume of 414,167. PRA Health Sciences has a twelve month low of $51.16 and a twelve month high of $84.38. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.01 and a quick ratio of 1.01. The stock has a market capitalization of $5,219.77, a P/E ratio of 30.28, a P/E/G ratio of 1.42 and a beta of 0.41.

PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, topping the consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The firm had revenue of $494.55 million for the quarter, compared to the consensus estimate of $477.89 million. During the same quarter in the previous year, the firm earned $0.64 earnings per share. The company’s quarterly revenue was up 23.7% compared to the same quarter last year. research analysts expect that PRA Health Sciences will post 3.2 EPS for the current year.

In related news, Director Matthew P. Young sold 5,115 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $79.90, for a total transaction of $408,688.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.10% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in PRAH. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in PRA Health Sciences by 12.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 160 shares in the last quarter. Carroll Financial Associates Inc. raised its stake in PRA Health Sciences by 127.4% during the third quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 790 shares in the last quarter. CAPROCK Group Inc. purchased a new stake in PRA Health Sciences during the second quarter valued at $208,000. Comerica Bank purchased a new stake in PRA Health Sciences during the third quarter valued at $214,000. Finally, Trustmark National Bank Trust Department purchased a new stake in PRA Health Sciences during the second quarter valued at $225,000. 98.51% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “PRA Health Sciences (PRAH) Given a $94.00 Price Target at Robert W. Baird” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/12/02/pra-health-sciences-prah-given-a-94-00-price-target-at-robert-w-baird.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.